Comparison of Free-breathing 3D Quantitative Perfusion in Patients With MINOCA and MINOCA-mimics
NCT ID: NCT06323811
Last Updated: 2024-03-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
75 participants
INTERVENTIONAL
2023-06-15
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The present study aims to:
* assess the microvascular function with a novel quantitative 3D myocardial perfusion imaging approach in the acute phase and post-convalescence
* refine the role and diagnostic potential of advanced quantitative CMR imaging
* assess the potential prognostic significance of microvascular dysfunction and epicardial adipose tissue on cardiovascular outcomes
Participants will undergo advanced CMR imaging in the acute setting (within 10 days after event) and post convalescence (after 3 months).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
xSPECT-based Myocardial Perfusion Scintigraphy: Consistency of Functional Values and Feasibility of Myocardial Uptake Quantitation in Patients With Suspected Coronary Artery Disease
NCT04583787
Dynamic CT Myocardial Perfusion Imaging
NCT02593838
Combined Non-invasive Coronary Angiography and Myocardial Perfusion Imaging Using 320 Detector Computed Tomography
NCT00934037
Breath-hold Cardiac Hybrid SPECT/CCTA
NCT02469051
Myocardial Contrast Echocardiography for the Assessment of the Infarct Related Artery & Risk Area in Patients w/ NSTEMI.
NCT02014701
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MINOCA
Patients with myocardial infarction with non-obstructive coronary artery disease (MINOCA) prospectively investigated with advanced CMR
CMR
Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence
Myocarditis
Patients with suspected myocarditis prospectively investigated with advanced CMR
CMR
Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence
Takotsubo cardiomyopathy
Patients with suspected Takotsubo cardiomyopathy prospectively investigated with advanced CMR
CMR
Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence
Spontaneous coronary artery dissection (SCAD)
Patients with suspected/diagnosed spontaneous coronary artery dissection prospectively investigated with advanced CMR
CMR
Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence
NSTEMI
Patients with confirmed non-ST elevation myocardial infarction on coronary angiography prospectively investigated with advanced CMR
CMR
Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CMR
Advanced CMR imaging including a novel quantitative free-breathing 3D perfusion sequence, 3D LGE imaging and a cine Dixon sequence
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* elevated cardiac biomarkers
* no signficant coronary artery disease on coronary angiogram or coronary CT
Exclusion Criteria
* severe asthma, chronic obstructive lung or kidney disease
* acute pulmonary embolism
* arrhythmia on ECG
* moderate to severe valvular disease
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
ETH Zurich
OTHER
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Robert Manka, Prof. MD
Role: PRINCIPAL_INVESTIGATOR
University of Zurich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital Zurich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Robert Manka
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COPE CMR
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.